ArticleBiochimica et biophysica acta2014
MEKK2 regulates focal adhesion stability and motility in invasive breast cancer cells.
Article in Biochimica et biophysica acta, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Structure-Based Design, Synthesis, and Evaluation of Novel Ponatinib Derivatives With a Significantly Altered Selectivity Profile.ChemMedChem · 2026Article
- MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities.International journal of molecular sciences · 2024Review
- Review
- Inhibitory effects of terrein on lung cancer cell metastasis and angiogenesis.Oncology reports · 2021Article
- MAP3K2 augments Th1 cell differentiation via IL-18 to promote T cell-mediated colitis.Science China. Life sciences · 2021Article
- CircPUM1 promotes hepatocellular carcinoma progression through the miR-1208/MAP3K2 axis.Journal of cellular and molecular medicine · 2021Article
- Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Cysteine Cathepsins Inhibition Affects Their Expression and Human Renal Cancer Cell Phenotype.Cancers · 2020Article
- Impact of ERK5 on the Hallmarks of Cancer.International journal of molecular sciences · 2019Review
- miR-302a inhibits human HepG2 and SMMC-7721 cells proliferation and promotes apoptosis by targeting MAP3K2 and PBX3.Scientific reports · 2019Article
- MiRNAs differentially expressed in skeletal muscle of animals with divergent estimated breeding values for beef tenderness.BMC molecular biology · 2019Article
- Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2).Biochemical and biophysical research communications · 2018Article
- Oncogenic signaling of MEK5-ERK5.Cancer letters · 2017Review
- Interaction with the Paxillin LD1 Motif Relieves MEKK2 Auto-inhibition.Journal of molecular signaling · 2015Article
- Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.Biochemical and biophysical research communications · 2015Article
- Dynamic self-guiding analysis of Alzheimer's disease.Oncotarget · 2015Review
- Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment.Clinical & experimental metastasis · 2015Article
- MEKK2 regulates paxillin ubiquitylation and localization in MDA-MB 231 breast cancer cells.The Biochemical journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
MEK Kinase 2 (MEKK2) is a serine/threonine kinase that functions as a MAPK kinase kinase (MAP3K) to regulate activation of Mitogen-activated Protein Kinases (MAPKs). We recently have demonstrated that ablation of MEKK2 expression in invasive breast tumor cells dramatically inhibits xenograft metastasis, but the mechanism by which MEKK2 influences metastasis-related tumor cell function is unknown. In this study, we investigate MEKK2 function and demonstrate that silencing MEKK2 expression in breast tumor cell significantly enhances cell spread area and focal adhesion stability while reducing cell migration. We show that cell attachment to the matrix proteins fibronectin or Matrigel induces MEKK2 activation and localization to focal adhesions. Further, we reveal that MEKK2 ablation enhances focal adhesion size and frequency, thereby linking MEKK2 function to focal adhesion stability. Finally, we show that MEKK2 knockdown inhibits fibronectin-induced Extracellular Signal-Regulated Kinase 5 (ERK5) signaling and Focal Adhesion Kinase (FAK) autophosphorylation. Taken together, our results strongly support a role for MEKK2 as a regulator of signaling that modulates breast tumor cell spread area and migration through control of focal adhesion stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.